Join to View Full Profile
825 Eastlake Ave ESeattle, WA 98109
Phone+1 206-288-6956
Dr. Gauthier is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Faculte Libre de Medecine de Lille, FranceClass of 2008
Certifications & Licensure
WA State Medical License 2014 - 2025
Clinical Trials
- A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Start of enrollment: 2022 Feb 21
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 1 citationsPhase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL.Jordan Gauthier, Emily C Liang, Jennifer J Huang, Erik L Kimble, Alexandre V Hirayama
Blood Advances. 2025-04-22 - The Impact of CMV Reactivation on Mortality After Chimeric Antigen Receptor T-Cell Therapy.Eleftheria Kampouri, Patrick W Flaherty, Hu Xie, Mandeep K Sekhon, Clementine Chalal
Blood Advances. 2025-04-09 - Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-y...Andrew J Portuguese, Jennifer J Huang, Yein Jeon, Mahnoosh Taheri, Aya Albittar
Haematologica. 2025-03-13
Abstracts/Posters
- Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T CellsClinically Relevant AbstractJordan Gauthier, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell TherapyJordan Gauthier, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical OutcomesJordan Gauthier, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lym...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Clinical Oncology Findings from Seattle Cancer Care Alliance (SCCA) Clinicians to Be Featured at the 2021 ASCO Annual MeetingJune 3rd, 2021- Seattle Cancer Care Alliance to Present New Research at 62nd Annual Meeting of the American Society of HematologyDecember 4th, 2020
Combination Therapy Boosts Durability of CAR T-cell Response in Hematologic CancersJanuary 10th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
